Hematocrit and TRT: When the Number Really Matters

The lab report says 53.4 percent, with an arrow pointing up. Your testosterone is finally where it should be, the symptoms are gone, and now this. Few findings raise the question of whether therapy can continue as quickly as a rising hematocrit.

An elevated hematocrit is the most common side effect of testosterone therapy and the most common reason a well-running treatment stalls. The value itself is less dramatic than its reputation, and the order in which you respond matters more than the number on the report.

What hematocrit measures

Hematocrit describes the share of blood volume made up of red blood cells. In men it normally sits between 40 and 52 percent. As it rises, blood becomes more viscous, and with viscosity comes more resistance for the heart to work against.

Testosterone intervenes in blood formation at several points. It first raises erythropoietin, the hormone that signals the bone marrow to produce red cells. It then shifts the set point between erythropoietin and hemoglobin upward, so the body defends a higher cell count as its new normal. At the same time it lowers hepcidin, the master regulator of iron metabolism, which makes more iron available for red cell production [2].

That explains why the rise is not a malfunction but an expected effect of the drug. It also explains why it cannot simply be removed without addressing the cause.

How much it rises depends on the delivery form

The strongest influence is not the dose on its own but the shape of the curve it produces. Short-acting injections create high peaks and carry the greatest risk of a pronounced rise among all delivery forms [1].

A comparison of three groups matched for age, body mass index and sleep apnea shows the range clearly. After 16 weeks, hematocrit had risen by 4.4 percentage points on intramuscular testosterone cypionate and by 1.7 points on implanted pellets, while it fell by 0.8 points on the intranasal preparation [6]. The groups were small, but the direction fits everything known about the link between peak levels and red cell production.

In practice: a man starting with a high baseline, or one who reacts sensitively, is better served by frequent small doses or a gel than by one large injection every three weeks. The differences between forms are covered in TRT gel vs. injection.

Why the baseline matters especially in Switzerland

Hematocrit is not purely a therapy value. It depends on how much oxygen reaches the blood, and that depends on where and how a man lives.

Living permanently at altitude raises the baseline physiologically. The effect starts at around 1,000 metres and grows with height, though in Swiss terms it stays moderate: between the plateau and Davos at 1,560 metres the gap is roughly one percentage point, and somewhat more in the Upper Engadine. That sounds like very little, and it decides the case precisely when a reading sits at 53 or 54 percent. A man from Sils Maria at 53 percent is not the same case as a man from Basel with the identical number.

Smoking and untreated sleep apnea push in the same direction. Both cause chronic oxygen shortage, which the body answers with more red cells. On top of that come genetic differences in sensitivity to testosterone, which explain why two men on an identical dose can follow completely different courses [1].

Hence the most important point about diagnostics: without a baseline taken before therapy starts, a value measured during therapy can only be half interpreted. Which values belong in the pre-treatment panel is set out in TRT blood work.

What 52 and 54 percent mean, and what they do not

Two thresholds are used in practice. From around 52 percent the value is monitored more closely and the dose reviewed. Above 54 percent the Endocrine Society guideline recommends interrupting therapy, investigating the cause, and restarting at a reduced dose [4].

These numbers are a sensible convention, not a physical cliff. A systematic appraisal of the evidence reaches an uncomfortable conclusion: the data showing that testosterone-induced erythrocytosis actually causes harm are scarce, and the cutoffs in the guidelines look chosen rather than derived [3].

That is not an argument for ignoring the value. It is an argument against panic at 53 percent and against the reflex to stop therapy immediately. A reading of 54.5 percent in a symptom-free non-smoker living on the plateau calls for an adjustment, not an exit.

The risk that is actually at stake

The reason for the attention is thrombosis. Viscous blood flows more slowly, and review articles do see an increased thrombotic risk with testosterone-induced erythrocytosis [2].

The largest safety trial in testosterone therapy supports this indirectly. TRAVERSE followed 5,246 men with existing cardiovascular disease or elevated risk for an average of 33 months. On the primary endpoint of cardiovascular death, heart attack and stroke, testosterone was not inferior to placebo: 7.0 versus 7.3 percent. What did occur more often in the testosterone group was atrial fibrillation, acute kidney injury and pulmonary embolism [5].

That is how it should be read. The cardiovascular case for therapy holds, and it holds across 5,246 patients. Hematocrit nonetheless remains the value where negligence has consequences.

The order of measures

If the value crosses the threshold, there is a sensible sequence. It does not start with phlebotomy.

First: dose and interval. Less drug per administration and shorter gaps flatten the peaks and reduce the stimulus on the bone marrow. That alone is often enough.

Second: the delivery form. Switching from injection to a gel is the single most effective lever, because it smooths the curve rather than merely cutting the amount.

Third: the co-factors. Stopping smoking, investigating sleep apnea, drinking enough. These three are routinely skipped, even though in an individual patient they can achieve more than any dose change.

Fourth: check the measurement itself. A hematocrit taken after a sauna, after a long day on the bike, or while dehydrated reads too high. Before drawing any conclusion from a borderline value, repeat it under normal conditions.

Only then: phlebotomy.

Phlebotomy is less obvious than its reputation

Phlebotomy lowers hematocrit reliably, which is why it appears in many recommendations. What is remarkable is how thin the basis for it is: robust evidence for the efficacy and safety of phlebotomy in testosterone-induced erythrocytosis is missing [2].

There is also a mechanism that argues against doing it automatically. Phlebotomy lowers tissue oxygen partial pressure and, when repeated, depletes iron stores. Both can trigger pathways that raise thrombotic risk rather than lower it. Practically, iron deficiency also causes fatigue and drops performance, bringing back precisely the symptoms that prompted treatment in the first place.

The authors' recommendation is therefore not a rejection but a shared decision: weigh the pros and cons together with the patient instead of scheduling phlebotomy as standard accompaniment [2]. And where it is used, it belongs on a doctor's order and in the record, not organised privately as a blood donation.

How often it is checked

Hematocrit belongs in every follow-up blood count, alongside testosterone and estradiol. A baseline before the start, a first check after roughly three months, and the usual rhythm afterwards make sense. With stable values a six-monthly measurement is enough later on; with a high baseline or after a dose change, more is needed.

For comparability the same rules apply as for hormone values: the same laboratory, in the morning, well hydrated, and no race or sauna session the day before. The draw itself can be done by any GP or walk-in laboratory, and basic insurance normally covers the cost.

If you are unsure whether your symptoms fit testosterone deficiency at all, the online self-test gives a first indication. Interpreting a specific result takes a conversation, and that is easily handled by telemedicine without a waiting room.

FAQ

At what hematocrit do I have to stop TRT?

Stopping is rarely necessary. From around 52 percent monitoring gets closer and the dose is reviewed; above 54 percent the guideline recommends an interruption followed by restarting at a reduced dose [4]. In most cases a smaller single dose, a shorter interval or a switch to gel is enough.

Is a high hematocrit dangerous?

It increases blood viscosity and with it thrombotic risk [2]. How much is less clear than the round cutoffs suggest: evidence for concrete harm from therapy-induced erythrocytosis is thin [3]. Take it seriously, but a single reading just above the threshold is not an emergency.

Why is my hematocrit rising even on a low dose?

Usually because of the curve, not the amount. Large single doses at long intervals produce peaks that stimulate the bone marrow more than the same weekly amount split into smaller administrations. Altitude, smoking, sleep apnea and individual sensitivity add to that [1].

Does donating blood help?

It lowers the number, but it does not replace work on the cause and it is not harmless: repeated phlebotomy depletes iron stores, and evidence for the benefit and safety of this approach is lacking [2]. Phlebotomy belongs on a doctor's order and under supervision, not self-organised.

I live in the Engadine and my value was high before therapy. What does that mean?

That your personal baseline is the reference point, not a textbook figure. At altitude a higher hematocrit is physiological. What matters is knowing the value before therapy starts and watching the trend, rather than holding a single number against a general limit.

Further Reading

• TRT blood work: which values are monitored
• TRT gel vs. injection: which form fits?
• TRT side effects: what actually occurs